| Autor: |
Kinoshita, Hannah, Cooke, Kenneth R., Grant, Melanie, Stanojevic, Maja, Cruz, Conrad Russell Young, Keller, Michael, Fortiz, Maria Fernanda, Hoq, Fahmida, Lang, Haili, Barrett, John, Liang, Hua, Tanna, Jay, Zhang, Nan, Shibli, Abeer, Datar, Anushree, Williams, Kirsten M., Dave, Hema, Dome, Jeffrey, Jacobsohn, David, Hanley, Patrick, Jones, Richard J., Bollard, Catherine M. |
| Zdroj: |
Blood; November 2021, Vol. 138 Issue: 1, Number 1 Supplement 1 p2828-2828, 1p |
| Abstrakt: |
Background: Patients with hematologic malignancies relapsing after allogeneic blood or marrow transplantation (BMT) have limited response to conventional salvage therapies with an expected 1-year overall survival (OS) of <20%. Current strategies to treat relapsed hematopoietic cancer after BMT, such as chemotherapy and donor lymphocyte infusions (DLI) to enhance the immunologic graft-versus-leukemia (GVL) effect, have low efficacy and are associated with graft-versus-host disease (GVHD). An alternative strategy to boost the GVL effect is to infuse donor-derived T-cells targeting tumor-associated antigen (TAA) peptides as circulating TAA-specific T-cells are associated with maintenance of remission post-BMT. In this phase-I study, we evaluated the safety and clinical outcomes following administration of a novel T-cell therapeutic targeting three TAAs, WT1, PRAME and survivin in patients with acute leukemia who relapsed or were at high-risk of relapse after allogeneic BMT. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
